Last reviewed · How we verify
Decavac™
Decavac is a recombinant vaccine designed to boost immune response against diphtheria, tetanus, and pertussis by providing booster immunization in adolescents and adults.
Decavac is a recombinant vaccine designed to boost immune response against diphtheria, tetanus, and pertussis by providing booster immunization in adolescents and adults. Used for Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults.
At a glance
| Generic name | Decavac™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant toxoid vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Decavac contains antigens from Corynebacterium diphtheriae toxoid, Clostridium tetani toxoid, and Bordetella pertussis components that stimulate adaptive immune responses. The vaccine is formulated to provide booster protection in individuals previously primed with childhood diphtheria-tetanus-pertussis vaccines, maintaining or enhancing antibody titers against these three pathogens.
Approved indications
- Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Post Marketing Surveillance for ADACEL™ in South Korea (PHASE4)
- Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. (PHASE3)
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (PHASE3)
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. (PHASE4)
- Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) (PHASE4)
- Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
- Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decavac™ CI brief — competitive landscape report
- Decavac™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI